Sab Biotherapeutics Stock Probability of Future Stock Price Finishing Under 4.28
| SABS Stock | USD 4.10 0.18 4.21% |
SAB |
SAB Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of SAB Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for SAB Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| SAB Biotherapeutics is way too risky over 90 days horizon | |
| SAB Biotherapeutics appears to be risky and price may revert if volatility continues | |
| SAB Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.24 M. Net Loss for the year was (42.19 M) with loss before overhead, payroll, taxes, and interest of (12.53 M). | |
| SAB Biotherapeutics currently holds about 16.62 M in cash with (25.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| SAB Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders |
SAB Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of SAB Stock often depends not only on the future outlook of the current and potential SAB Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. SAB Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.5 M | |
| Cash And Short Term Investments | 56.6 M |
SAB Biotherapeutics Technical Analysis
SAB Biotherapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. SAB Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of SAB Biotherapeutics. In general, you should focus on analyzing SAB Stock price patterns and their correlations with different microeconomic environments and drivers.
SAB Biotherapeutics Predictive Forecast Models
SAB Biotherapeutics' time-series forecasting models is one of many SAB Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary SAB Biotherapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about SAB Biotherapeutics
Checking the ongoing alerts about SAB Biotherapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for SAB Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| SAB Biotherapeutics is way too risky over 90 days horizon | |
| SAB Biotherapeutics appears to be risky and price may revert if volatility continues | |
| SAB Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.24 M. Net Loss for the year was (42.19 M) with loss before overhead, payroll, taxes, and interest of (12.53 M). | |
| SAB Biotherapeutics currently holds about 16.62 M in cash with (25.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| SAB Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders |
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.